Veru Inc. - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
VERU Nasdaq 2840 verupharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Veru Inc.

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss - Aug 4th, 2026 6:30 am
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th - Aug 3rd, 2026 6:30 am
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference - Jul 30th, 2026 6:30 am
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss - Jul 27th, 2026 6:10 am
Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty - Jul 9th, 2026 3:30 am
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day - Jul 7th, 2026 6:30 am
Veru And 2 Other Intriguing Penny Stocks To Watch - Jun 5th, 2026 6:05 am
Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial - Jun 5th, 2026 12:09 am
This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection? - Jun 4th, 2026 11:16 am
Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU) - Jun 4th, 2026 8:22 am
Earnings call transcript: Veru Inc Q2 2026 shows improved financials - May 31st, 2026 10:11 pm
Veru Inc. Q2 2026 Earnings Call Summary - May 15th, 2026 6:30 am
Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clinical Trial Results Amid ... - May 13th, 2026 5:03 pm
Transcript: Veru Q2 2026 Earnings Conference Call - May 13th, 2026 6:50 am
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - May 13th, 2026 4:30 am
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th - May 6th, 2026 6:30 am
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss - Mar 9th, 2026 6:30 am
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 19th, 2026 6:30 am
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Feb 11th, 2026 12:01 pm
Veru Inc. Q1 2026 Earnings Call Summary - Feb 11th, 2026 10:31 am